UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 OR 15(d) ofOF

~~The~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934

Date of Report (Date of earliest event reported): ~~October 21~~ November 6, 2025

INSULET CORPORATION

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Delaware

001-33462

04-3523891

(State or other jurisdictionof incorporation)

(CommissionFile Number)

(IRS EmployerIdentification No.)

(State or Other Jurisdictionof Incorporation)

(CommissionFile Number)

(IRS EmployerIdentification No.)

100 Nagog Park

Acton

Massachusetts

01720

(Address of principal executive offices)

(Zip Code)

(Address of Principal Executive Offices, including Zip Code)

Registrant’s telephone number, including area code:

(978)

600-7000

Not Applicable (Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act.			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act			☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 Par Value Per Share

PODD

The NASDAQ Stock Market, LLC

Item 52.02. ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

On ~~October 21~~November 6, 2025, ~~the Board of Directors (the "Board") of~~ Insulet Corporation (the "“Company"”) ~~appointed~~announced ~~Robbie~~its ~~Huffines~~financial asresults afor ~~Class~~the IIthird ~~director,~~quarter ~~effective~~ended ~~October~~September 3130, 2025. ~~Mr.~~The ~~Huffines~~full ~~will~~text ~~stand~~of ~~for~~the ~~election~~press byrelease ~~stockholders~~issued atin connection with the ~~Company’s~~announcement ~~2027~~is ~~Annual~~furnished ~~Meeting~~as ofExhibit ~~Stockholders~~99.1 ~~Mr. Huffines has been named~~ to ~~the~~this ~~Audit~~Current ~~Committee~~Report ofon ~~the~~Form ~~Board, effective October 31, 2025~~8-K.

~~Mr.~~The ~~Huffines~~information ~~was~~in athis ~~Global~~Item 2.02 ~~Chair~~ of ~~Investment~~this ~~Banking~~Current ~~and~~Report aon ~~member~~Form of8-K ~~the~~and ~~Executive~~Exhibit ~~Committee~~99.1 atshall JPnot ~~Morgan~~be ~~Chase~~deemed &“filed” ~~Co.~~for ~~from~~purposes ~~2020~~of ~~until~~Section 18 heof ~~retired~~the inSecurities ~~2024. From~~Act ~~2011~~of ~~to 2020~~1934, heas ~~was~~amended (the ~~company’s~~“Exchange ~~Vice~~Act”), ~~Chair~~or ofotherwise ~~Investment~~subject ~~Banking and from 2002~~ to ~~2010, he was~~ the ~~co-head~~liabilities of ~~the~~that ~~global~~Section, ~~healthcare~~nor ~~investment~~shall ~~banking~~it ~~group. Mr.~~be ~~Huffines~~deemed ~~began~~incorporated ~~his~~by ~~career~~reference atin JPany ~~Morgan~~filing ~~Chase~~by inthe ~~1992~~Company inunder the ~~mergers~~Securities ~~and~~Act ~~acquisitions~~of ~~group~~1933, ~~focusing~~as onamended, ~~healthcare. Prior~~or tothe ~~joining~~Exchange ~~J.P. Morgan Chase~~Act, ~~Mr.~~except ~~Huffines~~as ~~worked~~expressly atset ~~Alex~~forth ~~Brown~~by &specific ~~Sons,~~reference ~~specializing~~ in ~~equity~~such ~~financing and advisory assignments for emerging growth companies~~filing.

~~Mr.~~Item ~~Huffines is the co-founder of The Forest Group, a nonprofit organization dedicated to improving the mental health of children in underserved communities~~9. ~~He is currently a member of the board of directors of the Hastings Center for Biomedical Ethics, an independent, nonpartisan bioethics research institute, of Eikon Therapeutics, Inc~~01., aFinancial ~~pivotal-stage~~Statements ~~biotechnology company that works to develop new medicines to address grievous illnesses,~~ and ~~of Nextech Invest Ltd~~Exhibits., a cancer-focused venture capital firm headquartered in Zurich, Switzerland. He also served as a director of Walgreens Boots Alliance until its sale in August 2025. Mr. Huffines has an M.B.A. from the University of Virginia, where he received the Faculty Award for academic excellence. He has a B.A. from the University of North Carolina, where he majored in English and Economics.

There are no arrangements or understandings between Mr. Huffines and any other persons pursuant to which he was selected as a director. There are no transactions involving Mr. Huffines required to be disclosed under Item 404(a) of Regulation S-K. As a non-employee director of the Company, Mr. Huffines will receive cash and equity compensation pursuant to the Company's non-employee director compensation program, as described in the “Non-Employee Director Compensation” section of Company's proxy statement filed with the Securities and Exchange Commission on April 29, 2025, as may be adjusted by the Board from time to time.

Item 7.01 Regulation FD Disclosures.

On October 23, 2025, the Company issued a press release announcing the appointment of Mr. Huffines to the Board. A copy of that press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits


			(d)			Exhibits.

Exhibit No.						Description
ExhibitNo.						Description
99.1						Press Release dated ~~October~~November 236, 2025
104						Cover Page Interactive Date File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this ~~Current~~report ~~Report~~ to be signed on its behalf by the undersigned thereunto duly authorized.

INSULET CORPORATION

Date: October 23, 2025

By:

/s/ John W. Kapples

November 6, 2025

By:

/s/ Flavia H. Pease

John W. Kapples

Flavia H. Pease

Senior Vice President and General Counsel

Chief Financial Officer, Executive Vice President

Filing Compare · INSULET CORP